Home LifestyleHealth Biden: Vaccine production may be interrupted, and the United States may not be able to resume normal life this year.
Biden: Vaccine production may be interrupted, and the United States may not be able to resume normal life this year.

Biden: Vaccine production may be interrupted, and the United States may not be able to resume normal life this year.

by YCPress

February 20th – U.S. President Biden said on Friday (19th) local time that due to the sudden change of COVID-19 and the possible interruption of production of a vaccine in the United States, American life may not return to normal in 2021.

According to the New York Post on the 19th, Biden said during a visit to the Pfizer vaccine plant in Michigan that the mutation of the novel coronavirus and unpredictable vaccine production may expand the social and economic impact of the epidemic on the United States.

Biden said: “I believe that we will be close to normal by the end of this year.

But I can’t make a commitment to everyone. Other strains of the virus are raged in the U.S., and we don’t know what happens to vaccine productivity and things can change.”

Biden made the statement that there is widespread optimism that life is about to return to normal as the infection rate has declined and vulnerable people have been vaccinated.

Meanwhile, parts of the United States have been affected by extreme cold currents recently, slowing down the distribution of vaccines in 50 states, involving about 6 million doses, causing controversy about whether to save a second dose or give priority to more people to vaccinated.

The United States has been injected with more than 59 million doses of vaccine, or 17.8 doses per 100 people, according to Bloomberg’s analysis of public data.

But preliminary research shows that vaccines are less effective against more infectious coronavirus variants.

Fauci, an infectious disease expert in the United States, also said on the 19th that the new variant of the virus means that governments and companies will “have to be flexible to produce vaccines specifically targeted at mutations of the virus”.